Laboratoire Tilman has acquired Promogen
The shareholders of Promogen have sold the company to Laboratoire Tilman.
Founded in 1956, Laboratoire Tilman is a Belgium pharmaceutical laboratory specialized in the development, production and marketing of phytotherapy products and is the leader in the field of medicinal plants in Belgium. The company offers a range of more than 100 natural herbal solutions sold in over 30 countries, including best-selling products such as Flexofytol, Sedistress and Antimetil.
Founded in 2012, Promogen is an external independent French pharmaceutical network that promotes, sells and distributes a diverse portfolio, which includes medicines, medical devices, food supplements and cosmetics, through four brands, in the rheumatology, well-being, dermo-cosmetics, wound healing and fertility therapeutic areas. Promogen distributes its products to over 9,000 pharmacies and drugstores in France, through an in-house sales force of approximately 40 representatives.
Oaklins’ team in France acted as advisor to the shareholders of Laboratoire Tilman in this transaction.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more